Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets
February 22, 2019 6:47 AM ESTChardan Capital Markets analyst Keay Nakae raised the price target on Emergent BioSolutions (NYSE: EBS) to $71.00 (from $66.00) while maintaining a Buy rating.
The analyst commented, "We believe that the two recently announced acquisitions check a number of boxes that support he... More
